Provides molecular diagnostic tests for urological cancers, focusing on genetic testing to guide personalized treatment decisions.
MDxHealth SA operates as a precision diagnostics company at the forefront of commercial-stage urologic solutions. Serving markets across the United States, the Netherlands, Belgium, Spain, Poland, Italy, the rest of the European Union, and beyond, MDxHealth specializes in innovative genomic testing solutions for prostate cancer. Among its notable offerings are SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic test. These advanced diagnostic tools empower physicians with clinical pathways to identify prostate cancer with high accuracy, reducing the need for invasive procedures that carry inherent risks of complications.
Formerly known as OncoMethylome Sciences SA, MDxHealth SA rebranded in October 2010, reflecting its evolution and commitment to advancing diagnostic excellence. Established in 2003 and headquartered in Herstal, Belgium, the company continues to lead the charge in precision medicine, leveraging cutting-edge technology and robust research to improve patient outcomes. MDxHealth's innovative approach and global presence underscore its dedication to revolutionizing the diagnosis and management of urologic conditions, setting new standards in personalized healthcare.
Driven by a vision to redefine diagnostic accuracy and patient care, MDxHealth SA remains steadfast in its mission to provide healthcare providers and patients with reliable, actionable insights. Through ongoing innovation and strategic partnerships, the company strives to expand its diagnostic portfolio and make a meaningful impact in the field of urologic oncology worldwide.